Nano Miscellaneous
Market Cap
₹346 ₹346 Cr.
P/E
51.83
PEG = P/E ÷ 5yr forward EPS CAGR

The forward EPS CAGR is estimated individually for each company - factoring in its guidance, industry, and growth drivers - not generic rule-based projection.

Key Ratios

Debt to Equity
Debt to Equity
0.44
Div Yield (%)
Div Yield (%)
0.28
Individual < 2 lac
Individual < 2 lac
14.43 %
Institutions
Institutions
1.59 %
Market cap
Market cap
346 Cr
No. of Shareholders
No. of Shareholders
1,554
OPM (%)
OPM (%)
13.08 %
PE
PE
51.83
Prom Holding
Prom Holding
68.11 %
ROCE (%)
ROCE (%)
18.88
ROE (%)
ROE (%)
11.47
Sales
Sales
162 Cr
  • QMS Medi Allied Ser.
  • Nureca
  • 3B Blackbio Dx
Last updated on 28 Sep 2026
  • QMS distributes healthcare equipment and runs patient support services for pharma companies, hospitals and clinics. Products are about two-thirds of ~Rs173Cr FY26 revenue. Services are about one-third.
  • Its services are patient support programmes and screening camps run for pharma clients on cost-plus annual contracts. It also sells its own home-care devices alongside distributed brands and online.
  • QMS was a products distributor for ~30 years. It added services scale by buying disease-management provider Saarathi in 2024.
  • Profit rests on distributed products (10-12% EBITDA) and patient support programmes and camps (20-25%). Its own home-care devices brand Q-Devices is the growth leg.
  • It serves 50-plus pharma partners including top-10 firms. Per management, its edge is field execution with scientific marketing and tech.
  • QMS is moving patient-support services into Saarathi and keeping products in-house. It is adding an optics and diagnostics maker.
  • Working capital is intensive, with large receivables and inventory. Short-term borrowings of ~Rs67Cr sit against ~Rs173Cr of annual revenue.
  • Profit depends on H2 services ramp and services split and listing approval. Management guides ~Rs220Cr revenue and ~18% EBITDA margin for FY27, both maintained.
  • The promoter group holds ~68% of shares. Filings have carried misprints, including a Q1 services revenue correction.
  • FY27 revenue and margin path ~mid-Nov 2026
    the print shows revenue pace against the ~Rs220Cr guide and margin progress toward ~18%.
  • Home-care devices launches by Q3FY27
    the launches start the owned-devices scale-up toward 10-15% of FY27 revenue.
  • Optics and diagnostics acquisition by 30 Nov 2027
    the deal adds Rs113.81L of sales to a ~Rs173Cr base. The valuer-priced close needs scheme approval.
  • Services demerger and listing No timeline
    The scheme moves Rs37.17Cr of services, 24.41% of FY26 turnover, into Saarathi for listing. It needs NCLT, NSE and shareholder approvals.
  • New patient-support contracts No timeline
    new contracts add Rs5-7Cr toward the Rs100-105Cr patient-support revenue guide.
Price Range

See where the stock is trading versus its 52-week high and low.

Low
69
52W Range
High
217
Timeline

Key company specific updates.

Custom financial statement

Edit rows

Forensics

6 Yes

Positive for this company

3 Neutral

Neutral for this company

6 No

Negative for this company

2 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on QMS Medical Allied Services Ltd. Business

QMS Medical Allied Services Limited distributes a variety of medical devices, consumables, and its own branded products to clinics, pharmaceutical companies, and individual users. It includes medical consumables like disinfectants, filters, and wound management kits.

QMS Medi Allied Ser. major competitors are Nureca, 3B Blackbio Dx, TTK Healthcare, Poly Medicure, Rajnish Wellness, Health X Platform, Max India.
Market Cap of QMS Medi Allied Ser. is ₹378 Crs.
While the median market cap of its peers are ₹915 Crs.

QMS Medi Allied Ser. seems to be less financially stable compared to its competitors.
Altman Z score of QMS Medi Allied Ser. is 3.97 and is ranked 7 out of its 8 competitors.

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation Feb Nov May Aug Nov
Conference Call Aug Nov Feb May Aug Nov Sep Nov
Conference Call SummaryCon Call Summary

Discussions & Analysis

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material